Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of Allo-RevCAR01-T-CD123 in CD123-positive hematologic malignancies
NL-OMON60321Phase 1Recruiting
- Sponsor
- AvenCell Therapeutics
- Start
- Jun 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 1, single-arm trial of Allo-RevCAR01-T + R-TM123 in hematopoietic malignancies and acute myeloid leukemia (AML), sponsored by AvenCell Therapeutics. Started Jun 2024; status: recruiting.
02
Drugs
Allo-RevCAR01-T + R-TM123
03
Conditions
hematopoietic malignanciesacute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON60321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60321.